Full Prescribing Information for Nutropin AQ
Read Patient/Parent Instructions (4.09MB/PDF)

Nutropin AQ® [somatropin (rDNA origin) injection] is indicated for the treatment of growth hormone deficiency in children and adults, growth failure associated with chronic renal insufficiency prior to kidney transplantation, short stature associated with Turner syndrome, and long-term treatment of idiopathic short stature.

The Nutropin AQ Pen® [somatropin (rDNA origin) injection] was developed to give patients the option of a delivery device that provides simplicity, convenience, and safety features. The simple design makes it easy to use and easy to teach while a one-step, dial-back dose knob makes it easy to correct over-dialing errors. The small and light design makes the Nutropin AQ Pen convenient to carry while the dose flash recall reminds patients of last dose administered.

The Nutropin AQ Pen has few steps to delivery reducing the chance of error and the needle shield-lock protects against needle contamination and damage. The Nutropin AQ Pen is for exclusive use with Nutropin AQ Pen Cartridges. Healthcare professionals should provide patient training prior to use.

Status Nutropin AQ Pen received U.S. Food and Drug Administration (FDA) clearance in April 2002. The Nutropin AQ Pen represents the first device approval for Genentech and is available in the U.S. by prescription only.

Read more about Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin AQ Pen® Cartridge

Important Safety Information Nutropin is not for children and teenagers whose bones have finished growing.

Nutropin is not for patients who have certain types of eye disease caused by diabetes.

Nutropin is not for patients who have active cancer or any brain tumors.

Nutropin is not for patients who are critically ill after open heart surgery or abdominal (stomach) surgery, are severely hurt, or have severe breathing problems.

Nutropin is not for children and teenagers who have Prader-Willi syndrome and are very overweight or have trouble breathing.

Patients who are about to start taking Nutropin, or are already taking it, must tell their doctor about all of the medications they are taking, including supplements; if they have or develop a brain tumor; if they are given any new medication — especially cortisone, hydrocortisone, prednisone, prednisolone, dexamethasone, triamcinolone, or betamethasone; if they are pregnant or if they become pregnant; about any other condition or illness they have or develop.

As with any injection, patients may experience discomfort, soreness, or redness where Nutropin is injected.

Patients should contact their doctor immediately if they experience ongoing injection site discomfort; curvature of the spine (scoliosis); joint pain; puffy hands and/or feet (caused by fluid retention); changes in vision, a bad headache, or nausea with or without vomiting; hip or knee pain; a need to limp when they walk; pain in wrist (carpel tunnel); allergic reactions.

Patients must inject Nutropin at a different recommended place on their body each time. The doctor or nurse should supervise the first injection and provide training and instruction.